The global High Potency APIs market size is expected to grow from $22.61 billion in 2021 to $24.53 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The HP APIs market is expected to reach $34.04 billion in 2026 at a CAGR of 8.5%.
What is the Global HP (High Potency) APIs Market?
The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services. High potency APIs are extremely effective in pharmacologically active ingredients. These are highly specific in their action and offer significant efficiency even at the low daily therapeutic doses. HPAPIs are used in formulations for high potent drugs, owing to their ability to target precise disease cells including cancer cells.
Get a Sample of the global HP (high potency) APIs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2814&&type=smp
What drives the Global HP (High Potency) APIs Market?
The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the high potency APIs market. Rising incidence of cancer is resulting in increasing R&D about anticancer drugs which in turn is propelling the demand for high potency APIs market. According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market.
Get the full global HP (high potency) APIs industry report here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2814&&type=smp
Global HP (High Potency) APIs Market Segments
The global HP (high potency) APIs market is segmented:
By Type: Innovative HPAPI, Generic HPAPI
By Synthesis Type: Synthetic HPAPI, Biotech HPAPI
By Therapeutic Application: Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)
By Geography: The regions covered in the HP (high potency) APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
HP (High Potency) APIs Global Market Report 2022provides market size and growth forecasts for the global HP (high potency) APIs market, global HP (high potency) APIs market share, HP (high potency) APIs market segments and geographies, HP (high potency) APIs market competitive landscape including leading competitors’ revenues, profiles and market shares. The HP (high potency) APIs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global HP (High Potency) APIs Industry Playersinclude Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc., BASF SE, Covidien plc, Boehringer Ingelheim GmbH, Merck & Co. Inc., Sigma Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan Inc., AbbVie, AstraZeneca plc and GlaxoSmithKline PLC. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
